Blockade Of The Cxcl12/Cxcr4 Axis With Amd3100 Induces Multimodal Antitumor Effects In Murine Ovarian Cancer And Prolongs Survival

The chemokine, CXCL12, and its receptor, CXCR4, have been shown to be expressed by various tumors including ovarian cancer. CXCL12/CXCR4 expression by tumors has been associated with enhanced progression including tumor cell proliferation, invasion, and angiogenesis. We proposed that modulation of the CXCL12/CXCR4 axis in ovarian cancer would have multimodal effects on tumor pathogenesis. This was addressed using RNAi technology and a selective CXCR4 antagonist, AMD3100, in an immunocompetent mouse model of intraperitoneal papillary epithelial ovarian cancer derived from a syngeneic cell line (BR5–1) that constitutively expresses both CXCL12 and CXCR4. CXCL12 knockdown of BR5–1 cells using RNAi reduced cell proliferation in vitro (p Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-387. doi:10.1158/1538-7445.AM2011-LB-387